There are three major isoforms of apolipoprotein E (called apoE2, apoE3 and apoE4) that arise from a single gene locus and differ from each other only by single amino acids. It is now well-established that the major risk factor for the development of late-onset Alzheimer's disease (accounting for about 90% of cases of dementia) is the presence of the apoE4 isoform. This protein is so insidious that individuals with two copies of apoE4 will develop Alzheimer's disease by age 70. Our hypothesis is that the difference in the interaction of apoE isoforms with amyloid-b, the major protein in amyloid plaques, is responsible for the functional differences between apoE isoforms. There is considerable evidence that Ab clearance from cells is a defining factor in the development of Alzheimer's disease and is apoE isoform dependent. Our goal is to understand the apoE-Ab interaction. There are three specific aims: To understand the kinetics and mechanism of Ab aggregation, to understand the apoE- Ab and apoE-Ab-lipid interaction and to find small molecules that perturb these interactions. The apoE-Ab interaction is poorly understood. Thus, the Ab binding site on apoE, the forms of Ab that bind apoE, the role of lipid in Ab binding and the mechanism of Ab binding to apoE are largely unknown. We have shown that apoE interacts only with intermediates that occur during Ab aggregation making it is essential to understand the mechanism of Ab aggregation itself. We ask what those intermediates are and how they define the interaction with apoE using new fluorescence assays we have developed that first determine the rate and equilibrium constants for the formation of oligomers during the Ab aggregation and secondly examine the aggregation process beyond oligomer formation. These methods will be then used to understand the role of lipid on the apoE-Ab interaction. We will use our recent observation of structural differences between apoE3 and apoE4, differences distant from the site of the single amino acid change, as the basis for examining the differences in the interaction between apoE isoforms and Ab. Specific regions/residues of both apoE and Ab involved in their interaction will be determined by site-directed mutations and/or hydrogen/deuterium exchange procedures. These methods, along with high throughput screening experiments we propose, will be used to differentiate the behavior of apoE4 relative to that of apoE3 with respect to the interaction with Ab. The results may lead to the new ideas concerning the development of therapeutic agents to delay the onset of Alzheimer's disease. In collaboration with others at Washington University any small molecule compounds that do so will be tested for their ability to affect Ab clearance in mouse brain. Of critical importance is the availability of the structure of a full-length monomeric form of apoE3 (34 kDa), the only known full-length structure of any apoE isoform.

Public Health Relevance

Late-onset Alzheimer's Disease is the most common cause of dementia. Its prevalence is ~10% for those over 65 and up to ~50% for those over 85. The major risk factor for development of this disease is the presence of a form of apolipoprotein E called apoE4. We propose that it is the interaction of apoE4 with the Abeta peptide that leads to formation of dense amyloid plaques characteristic of Alzheimer's disease. The work of this proposal searches for therapeutic agents that specifically interfere with the interaction between apoE4 and Abeta.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Multi-Year Funded Research Project Grant (RF1)
Project #
Application #
Study Section
Biophysics of Neural Systems Study Section (BPNS)
Program Officer
Petanceska, Suzana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Frieden, Carl; Wang, Hanliu; Ho, Chris M W (2017) A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions. Proc Natl Acad Sci U S A 114:6292-6297
Wang, Hanliu; Rempel, Don L; Giblin, Daryl et al. (2017) Peptide-Level Interactions between Proteins and Small-Molecule Drug Candidates by Two Hydrogen-Deuterium Exchange MS-Based Methods: The Example of Apolipoprotein E3. Anal Chem 89:10687-10695
Mondal, Tridib; Wang, Hanliu; DeKoster, Gregory T et al. (2016) ApoE: In Vitro Studies of a Small Molecule Effector. Biochemistry 55:2613-21
Frieden, Carl (2015) ApoE: the role of conserved residues in defining function. Protein Sci 24:138-44
Garai, Kanchan; Verghese, Philip B; Baban, Berevan et al. (2014) The binding of apolipoprotein E to oligomers and fibrils of amyloid-? alters the kinetics of amyloid aggregation. Biochemistry 53:6323-31